Abeona Therapeutics Inc
NASDAQ:ABEO 4:00:00 PM EDT
| Market Cap (Intraday) | 66.64M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.92 |
| 50-Day MA | $3.96 |
| 200-Day MA | $4.85 |
Abeona Therapeutics Inc Stock, NASDAQ:ABEO
1330 Avenue of the Americas, 33rd floor, New York, New York 10019
United States of America
Phone: +1.646.813.4701
Number of Employees: 90
Description
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.